Abstract
With the innovation of radiotherapy equipment and the promotion of targeted therapy and immunotherapy, the therapeutic mode and status of radiotherapy in non-small cell lung cancer (NSCLC) are constantly changing. For early NSCLC, stereotactic radiotherapy may be an alternative to surgery, but the optimal segmentation model still needs to be explored. As for locally advanced NSCLC, postoperative radio-therapy is still controversial for operable patients, the results of consolidated immunotherapy after concurrent chemoradiotherapy in inoperable patients are encouraging, prophylactic cranial irradiation does not improve survival. Local radiotherapy for patients with oligometastasis is expected to prolong survival. Key words: Carcinoma, non-small-cell lung; Radiotherapy; Treatment outcome; Prognosis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
